The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Combination of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor, with pembrolizumab in patients with triple negative breast cancer and adenocarcinoma of the lung.
 
Murray Yule
Employment - BerGenBio
Leadership - BerGenBio
Stock and Other Ownership Interests - BerGenBio
 
Kjersti Davidsen
No Relationships to Disclose
 
Magnus Bloe
Employment - BerGenBio
Stock and Other Ownership Interests - BerGenBio
 
Linn Hodneland
Employment - BerGenBio
 
Agnete Engelsen
No Relationships to Disclose
 
Maria Lie
No Relationships to Disclose
 
Sebastien Bougnaud
No Relationships to Disclose
 
Stacey D'Mello
No Relationships to Disclose
 
Kristina Aguilera
Employment - BerGenBio
 
Lavina Ahmed
Employment - BerGenBio
 
Agata Rybika
Employment - BerGenBio
 
Eline Milde Naeval
Employment - BerGenBio
 
Anna Boniecka
Employment - BerGenBio
 
Jean Paul Thiery
No Relationships to Disclose
 
Salem Chouaib
Research Funding - BerGenBio
 
Rolf A. Brekken
Research Funding - BerGenBio
 
Gro Gausdal
Employment - BerGenBio
 
James Lorens
Employment - BerGenBio
Leadership - BerGenBio
Stock and Other Ownership Interests - BerGenBio
Research Funding - BerGenBio
Patents, Royalties, Other Intellectual Property - BerGenBio